{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Gel+Dosage&page=2",
    "query": {
      "intervention": "Placebo Gel Dosage",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 203,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Gel+Dosage&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Gel+Dosage&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T19:41:55.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03522441",
      "title": "Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Clindamycin 1% Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akorn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1125,
      "start_date": "2018-04-27",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 10,
      "location_summary": "Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522441"
    },
    {
      "nct_id": "NCT01880320",
      "title": "Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "CD0271 0.3% / CD1579 2.5%",
          "type": "DRUG"
        },
        {
          "name": "CD0271 0.1% / CD1579 2.5%",
          "type": "DRUG"
        },
        {
          "name": "Topical Gel Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 503,
      "start_date": "2013-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2018-06-28",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01880320"
    },
    {
      "nct_id": "NCT02580370",
      "title": "Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Skin Aging"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo comparator",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 450,
      "start_date": "2015-09",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 1,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02580370"
    },
    {
      "nct_id": "NCT00446472",
      "title": "Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcers"
      ],
      "interventions": [
        {
          "name": "Regranex®",
          "type": "DRUG"
        },
        {
          "name": "Hydrogel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California Institute for Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-04",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2010-06-04",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • Los Angeles, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446472"
    },
    {
      "nct_id": "NCT01670032",
      "title": "Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Impetigo"
      ],
      "interventions": [
        {
          "name": "Experimental: CD07223 1.5 % Topical Gel BID",
          "type": "DRUG"
        },
        {
          "name": "Experimental: CD07223 1.5% Topical Gel TID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel TID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NovaBay Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2012-08",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-08-12",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 7,
      "location_summary": "Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Gresham",
          "state": "Oregon"
        },
        {
          "city": "Cheraw",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670032"
    },
    {
      "nct_id": "NCT04589611",
      "title": "Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Post-traumatic Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "amobarbital/Gel-One (one dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (single dose)",
          "type": "DRUG"
        },
        {
          "name": "amobarbital/Gel-One (two doses)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (two doses)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "J L Marsh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-07-20",
      "completion_date": "2025-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04589611"
    },
    {
      "nct_id": "NCT04759664",
      "title": "LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EGFRI Induced Acneiform Lesions"
      ],
      "interventions": [
        {
          "name": "LUT014 Gel (Dose 1)",
          "type": "DRUG"
        },
        {
          "name": "LUT014 Gel (Dose 2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lutris Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2021-04-12",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 17,
      "location_summary": "Glendale, California • Santa Monica, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759664"
    },
    {
      "nct_id": "NCT01601236",
      "title": "Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Repository Corticotropin Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-05",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 10,
      "location_summary": "Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more",
      "locations": [
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01601236"
    },
    {
      "nct_id": "NCT02465320",
      "title": "COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Biopsy"
      ],
      "interventions": [
        {
          "name": "COL-1077",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juniper Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 75 Years · Female only"
      },
      "enrollment_count": 187,
      "start_date": "2015-05",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 23,
      "location_summary": "Norwalk, California • Colorado Springs, Colorado • Lakewood, Colorado + 19 more",
      "locations": [
        {
          "city": "Norwalk",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465320"
    },
    {
      "nct_id": "NCT02866695",
      "title": "Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "ingenol mebutate gel 0.015%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-10-06",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-04T19:41:55.956Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02866695"
    }
  ]
}